# A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma

> **NCT02035657** · PHASE1 · COMPLETED · sponsor: **Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 10 (actual)

## Conditions studied

- Merkel Cell Carcinoma

## Interventions

- **BIOLOGICAL:** GLA-SE

## Key facts

- **NCT ID:** NCT02035657
- **Lead sponsor:** Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2018-03
- **Final completion:** 2018-03
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2018-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02035657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02035657, "A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02035657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*